

FOR IMMEDIATE RELEASE

Biolux Research Announces OsseoPulse™ Production Milestone and Expanding Distribution

VANCOUVER, B.C., CANADA – June 26, 2009 – Biolux Research Ltd. is pleased to announce today that we have achieved a production milestone for our OsseoPulse™ Bone Regeneration System, and have expanded our product distribution into additional markets.

Since launching the OsseoPulse™ in Canada in Oct. 2008, we have received regulatory clearance in Canada, Korea, Israel, and Europe. Achieving CE Mark is a significant achievement as it provides direct regulatory approval for approximately 20 European countries.

In the 8 months since OsseoPulse™ launch, we have manufactured and shipped over 300 units, for an average of approximately 40 units per month. The majority of devices have been sold through our partner in Korea, DIO Implant, and our partner in Canada, Citagenix Inc. Letters of intent have been signed with, and OsseoPulse™ devices have been sold to, new distributors in Turkey and Thailand, as well as potential partners in the UK, Israel, France, Austria, Japan, Argentina, and Iran.

"We are truly pleased with our initial progress in commercializing the OsseoPulse™ and the positive response from the market, and wish to thank all of our partners and stakeholders for their support" states Kevin Strange, President and CEO of Biolux. "We are very appreciative of the spirit of collaboration and efforts of our main partnerships with DIO and Citagenix, and excited about our new channel partners and prospects throughout the world. We are also grateful for the continuing support of our advisers and investigators, and for the significant product engineering and manufacturing support from StarFish Medical. We anticipate establishing the OsseoPulse™ as a significant new approach to accelerating bone regeneration in implantology and reducing treatment times for patients."

About Biolux Research

Biolux Research Ltd. is a world leader in the development of light activated bone regeneration systems for dentistry. Biolux focuses on product development, clinical and basic research, and its proprietary, patent-pending OsseoPulse™ Bone Regeneration System is premised on a vision to transform the practice of implantology and oral surgery in dentistry by accelerating implant integration and bone regeneration in a safe, effective and non-invasive approach. www.bioluxresearch.com

For More Information:

Kevin Strange
President & CEO
Biolux Research Ltd.
+1 (250) 686-1120
k.strange@bioluxresearch.com